Nova Biomedical Acquires NanoCellect Assets to Enhance Cell Line Development Workflows
Nova Biomedical announced on July 25, 2026, an transaction involving certain assets from NanoCellect, a provider of microfluidic cell sorting technology. The move enhances Nova's capabilities in cell line development.
WALTHAM, Massachusetts – Nova Biomedical announced on July 25, 2026, a transaction concerning certain assets from NanoCellect, a provider of microfluidic cell sorting technology. This acquisition expands Nova Biomedical's cell line development expertise, strengthening its ability to support biopharmaceutical workflows from early development through manufacturing.
The NanoCellect WOLF G2® cell sorting platform facilitates gentle, microfluidic cell selection and isolation. It complements Nova Biomedical's existing Solentim portfolio, which focuses on cloning, verification, and growth analysis. Together, these technologies offer a more integrated approach to cell line development by linking cell selection, single-cell isolation, and highly reliable clone verification.
Nova Biomedical aims to provide a more cohesive technology portfolio that supports continuity, insight, and decision-making throughout the bioprocessing lifecycle. This expansion is expected to accelerate cell line development timelines and improve clone selection outcomes. It also establishes a stronger foundation for process development, scaling, and manufacturing operations.
"NanoCellect adds a crucial upstream capability to our portfolio and enhances our ability to link key steps in cell line development," said John Luck, President of Nova Biomedical's Biopharmaceutical Business Unit. "By integrating cell sorting with clone isolation and reliable verification, along with analytical checkpoints like cell culture monitoring and osmolality, we can help our customers find a suitable clone faster and gain insights that optimize clone selection and ensure better performance during process development, scale-up, and manufacturing."